Key result
Aldosterone-receptor antagonists are recommended for patients with primary aldosteronism, resistant hypertension, and hypertension with hypokalemia, despite a lack of definitive randomized trial data.
Why the study?
Do aldosterone-receptor antagonists benefit patients with resistant hypertension?
Do aldosterone-receptor antagonists benefit patients with resistant hypertension?
This review recommends the use of aldosterone-receptor antagonists for patients with primary aldosteronism, resistant hypertension, and hypertension with hypokalemia.
No takes yet. Share an insight, caveat, or question.
Supports guideline recommendations for aldosterone-receptor antagonists in resistant hypertension; leaves open confirmation from randomized trials.
Jansen et al. (2009) conducted a review in Hypertension. Aldosterone-receptor antagonists (ARAs) was evaluated. Aldosterone-receptor antagonists are recommended for patients with primary aldosteronism, resistant hypertension, and hypertension with hypokalemia, despite a lack of definitive randomized trial data.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: